Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07662109 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Not yet
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
NCT07662109: Clinical Trial Phase 3 study, sponsored by AstraZeneca.
NCT07662109 is a Phase 3 study that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 2,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07662109, a Phase 3 study, has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Interventions
- DRUG Dapagliflozin
- DRUG Elecoglipron
- DRUG Elecoglipron-matched placebo
- DRUG Dapagliflozin-matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-07-06 |
| Est. Completion | 2028-07-05 |
| Phase | Phase 3 |
What is known before NCT07662109 opens enrollment
NCT07662109 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher).
The record links to 0 conditions, and to 4 interventions - of which Dapagliflozin is the first listed.
NCT07662109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07662109 about?
NCT07662109 is a clinical study titled "A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated w...
What is the current status of trial NCT07662109?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2026-07-06. Estimated completion is 2028-07-05.
What interventions are being tested in trial NCT07662109?
The interventions under investigation include: Dapagliflozin (DRUG), Elecoglipron (DRUG), Elecoglipron-matched placebo (DRUG), Dapagliflozin-matched placebo (DRUG).
Who is sponsoring clinical trial NCT07662109?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07662109's enrollment target sits among peer trials
2,000 100th of 2000 higher than 1,895 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI